/HURA
HURA Stock - TuHURA Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$0.82-7.69%
$0.07 (-7.69%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.90
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HURA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.81 – $0.83
TARGET (TP)$0.94
STOP LOSS$0.75
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.03
52W High$5.50
52W Low$0.80
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-116,710 | N/A | N/A | N/A | $-32,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-17,649,492 | $-29,764,720 | $-9,933,851 | $-7,254,981 | $-21,572,000 |
| Net Income | $-21,682,306 | $-29,316,825 | $-9,367,513 | $-7,016,509 | $-38,298,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.21 | $-11.29 | $-324.48 | $-903.03 | $-2805.84 |
Company Overview
TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$13
Average Target
↑ 1488.1% Upside
Now
$11
Low
$13
Average
$15
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 3rd 2025 | H.C. Wainwright | Initiation | Buy | $13 |
| December 19th 2024 | Rodman & Renshaw | Initiation | Buy | $11 |
| November 5th 2024 | Maxim Group | Initiation | Buy | $15 |
Earnings History & Surprises
HURABeat Rate
40%
Last 10 quarters
Avg Surprise
-2141.7%
EPS vs Estimate
Beats / Misses
4/6
Last 12 quarters
Latest EPS
$-0.14
Q4 2025
EPS Surprise History
Q4 23
-68.5%
$-8.26vs$-4.90
Q2 24
+99.4%
$-0.05vs$-8.75
Q2 24
No data
Q4 24
-1270.0%
$-1.37vs$-0.10
Q1 25
-9222.2%
$-8.39vs$-0.09
Q2 25
-15.4%
$-0.15vs$-0.13
Q3 25
-50.0%
$-0.21vs$-0.14
Q4 25
+6.7%
$-0.14vs$-0.15
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | $-0.15 | $-0.14 | +6.7% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.14 | $-0.21 | -50.0% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.13 | $-0.15 | -15.4% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $-0.09 | $-8.39 | -9222.2% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.10 | $-1.37 | -1270.0% | ✗ MISS |
Q2 2024 | Jun 30, 2024 | — | $-1.47 | — | — |
Q2 2024 | May 14, 2024 | $-8.75 | $-0.05 | +99.4% | ✓ BEAT |
Q4 2023 | Dec 31, 2023 | $-4.90 | $-8.26 | -68.5% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $-36.92 | $-0.09 | +99.7% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | — | $-68.99 | — | — |
Q1 2023 | Mar 31, 2023 | $-3.50 | $-389.54 | -11029.8% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | $-110.25 | $-73.58 | +33.3% | ✓ BEAT |
Q3 2022 | Sep 30, 2022 | — | $-109.87 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-145.43 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-190.79 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-212.51 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-304.56 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-359.85 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-396.66 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-381.28 | — | — |
Latest News
TuHURA Biosciences Announces Kintara's REM-001 Trial Meets Primary Endpoint In Metastatic Cutaneous Breast Cancer
📈 PositiveBenzinga•Dec 15, 2025, 12:51 PM•Also:
TuHURA Biosciences Updates Portfolio Including VISTA Symposium In AML; $15.6M Financing Extends Runway For Key Phase 3 Milestones
📈 PositiveBenzinga•Dec 11, 2025, 12:39 PM
TuHURA Biosciences shares are trading lower after the company announced a $15.6 million registered direct offering of 9,462,423 shares at $1.65 per share.
📉 NegativeBenzinga•Dec 9, 2025, 04:43 PM
TuHURA Biosciences Announces $15.6M Registered Direct Offering Of 9,462,423 Shares At $1.65/Share
➖ NeutralBenzinga•Dec 9, 2025, 02:51 PM
TuHURA Biosciences Highlights Its Research On Potential Role Of DOR In Controlling Immunosuppressive Capabilities Of MDSCs In Oral Presentation At ASH Annual Meeting And Exposition
📈 PositiveBenzinga•Dec 8, 2025, 12:52 PM
TuHURA Biosciences Q3 EPS $(0.14) Beats $(0.15) Estimate
📈 PositiveBenzinga•Nov 14, 2025, 12:39 PM
TuHURA Biosciences Files For Mixed Shelf Of Up To $250M
➖ NeutralBenzinga•Nov 3, 2025, 10:43 PM
TuHURA Biosciences To Present First Evidence Of Delta Opioid Receptor's Role In Reprogramming Immunosuppressive Cells At ASH 2025
📈 PositiveBenzinga•Nov 3, 2025, 02:15 PM
TuHURA R&D Jumps 75% in Q2
📈 PositiveThe Motley Fool•Aug 15, 2025, 02:01 AM
Frequently Asked Questions about HURA
What is HURA's current stock price?
TuHURA Biosciences, Inc. (HURA) is currently trading at $0.82 per share. The stock has moved -7.69% today.
What is the analyst price target for HURA?
No analyst price targets are currently available for this stock.
What sector is TuHURA Biosciences, Inc. in?
TuHURA Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is HURA's market cap?
TuHURA Biosciences, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does HURA pay dividends?
No, TuHURA Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABOS
Acumen Pharmaceuticals, Inc.
$2.15
Mkt Cap: $0.1B
AGEN
Agenus Inc.
$3.44
Mkt Cap: $0.1B
CGTX
Cognition Therapeutics, Inc.
$1.54
Mkt Cap: $0.1B
INO
Inovio Pharmaceuticals, Inc.
$2.28
Mkt Cap: $0.1B
IRD
Opus Genetics, Inc.
$2.00
Mkt Cap: $0.1B
MCRB
Seres Therapeutics, Inc.
$14.98
Mkt Cap: $0.1B
SEER
Seer, Inc.
$1.79
Mkt Cap: $0.1B
SPRO
Spero Therapeutics, Inc.
$2.32
Mkt Cap: $0.1B
TVGN
Tevogen Bio Holdings Inc.
$0.38
Mkt Cap: $0.1B
VTGN
VistaGen Therapeutics, Inc.
$0.78
Mkt Cap: $0.0B
Explore stocks similar to HURA for comparison